PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double strike: engineered immune cells and targeted pill take on tough leukemia
Disease control Recruiting nowThis study tests a new approach for people newly diagnosed with a specific, aggressive leukemia (Ph+ ALL). It combines a single infusion of specially engineered immune cells (CAR-T cells) with a daily targeted pill (olverembatinib). The goal is to see if this powerful one-two pun…
Matched conditions: PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to keep leukemia in remission after transplant
Disease control Recruiting nowThis early-phase trial is testing the drug asciminib as a maintenance treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who have already received a stem cell transplant or CAR T-cell therapy. The goal is to see if asciminib is safe …
Matched conditions: PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Leukemia drug Asciminib's Long-Term safety tracked in ongoing study
Disease control Recruiting nowThis study follows people with chronic myeloid leukemia (CML) who have already benefited from the drug asciminib in earlier Novartis trials. Researchers want to see how safe the drug is over the long term. About 347 participants will continue taking asciminib or other similar dru…
Matched conditions: PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to control tough leukemia
Disease control Recruiting nowThis study tests whether combining two drugs, blinatumomab and asciminib, can help control Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The trial enrolls 40 adults who are not good candidates for strong chemotherapy. Researchers will monitor safety and…
Matched conditions: PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy shows promise against Hard-to-Treat leukemia
Disease control Recruiting nowThis study tests a combination of two drugs, blinatumomab and ponatinib, along with standard chemotherapy, in people with a specific type of acute lymphoblastic leukemia (ALL) that has a genetic change called the Philadelphia chromosome. The goal is to see if this mix can better …
Matched conditions: PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a daily pill stop leukemia relapse after transplant?
Disease control Recruiting nowThis early-phase study tests the safety and best dose of asciminib, a daily pill, in adults with a certain type of leukemia (Ph+ ALL) who have already received a stem cell transplant or CAR T therapy. The goal is to see if taking asciminib afterward can help prevent the cancer fr…
Matched conditions: PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take on philadelphia Chromosome-Positive leukemia
Disease control Recruiting nowThis study tests whether specially engineered immune cells (CAR-T cells) can treat adults with a specific, aggressive form of acute lymphoblastic leukemia that has a genetic marker called the Philadelphia chromosome. Fifty newly diagnosed patients will receive an infusion of thes…
Matched conditions: PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC